혈우병 (Hemophilia)

소개글

"혈우병 (Hemophilia)"에 대한 내용입니다.

목차

1. Key Factors and Causes
2. Case Study Summary
3. New Technology, Breakthroughs, and Research
4. Impact and Effectiveness
5. Recommendations
6. Conclusion

본문내용

According to the CDC (2018), hemophilia occurs in about 1 in 5,000 male births, and currently, it is estimated that about 20,000 men in the United States suffer from this disease. Hemophilia A type is about four times that of type B hemophilia, and half of the hemophilia patients are severe forms (CDC, 2018). The mortality rate for hemophilia patients is about 2 times higher than for healthy men and 4-6 times higher for patients with severe hemophilia (Henderson, 2017). Unfortunately, hemophilia sufferers have a 10-year shorter average life expectancy than men, even when adequately treated (Henderson, 2017). Also, most people with hemophilia who do not receive adequate treatment die before they become adults. However, the success of today's genetic experiments and the development of various medicines suggest the possibility of treating hemophilia (Iorio et al., 2018). Therefore, it is possible to prolong the lifespan of hemophilia patients by providing patients and families with genetic information about the disease, preventing complications of bleeding, providing safety management, and treating hemophilia through genetic techniques.
Key Factors and Causes
Hemophilia is a bleeding disorder that slows the blood clotting process. The main types of hemophilia are hemophilia A (classical hemophilia or factor VIII deficiency) and hemophilia B (Christmas disease or factor IX deficiency) (NIH, 2019). Both types of signs and symptoms are similar but are caused by mutations in other genes.

참고 자료

없음